Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

"Lap Band" weight loss surgery improves physical, psychological health in extremely obese adults

One year after weight loss surgery with laparoscopic gastric banding, extremely obese adults demonstrate not only better physical health but also improved psychological health, a new study shows. The results will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Spark Together for Health Kids program promotes access to physical activity, healthy food

A new survey by the Heart and Stroke Foundation of Ontario found the majority of kids in the Greater Toronto Area (GTA) will be missing out on physical activity this summer, as parents scramble to find child care solutions once school is out.

21 Jun 2010

Obese women with insulin resistance lose more weight on lower-carbohydrate diet: Study

Obese women with insulin resistance lose more weight after three months on a lower-carbohydrate diet than on a traditional low-fat diet with the same number of calories, according to a new study. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique platform technology, ZYOG1 is a novel, oral, anti-diabetic molecule.

21 Jun 2010

Research findings open door to new model for health and fitness measurement

A University of Southern California study appearing in the current issue of peer-review journal, Nutrition Research reports that the user-friendly, Web-native Stayhealthy BC1 System offers clinical-grade body composition analysis comparable to the most rigorous clinical tools. According to the company, the study's findings open the door to a new, far more effective and engaging model for health and fitness measurement, reporting body composition analysis, rather than body weight or the outdated body mass index.

19 Jun 2010

Artificial pancreas system reduces risk of nocturnal hypoglycemia

An article recently published in The Lancet reports that using an artificial pancreas system overnight can significantly reduce the risk of nocturnal hypoglycemia in children and adolescents with type 1 diabetes. Moreover, the first clinical trial of an artificial pancreas system delivering both insulin and glucagon has shown that this system can prevent development of hypoglycemia.

19 Jun 2010

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

The non-profit Inamori Foundation (President: Dr. Kazuo Inamori) today announced that Dr. Shinya Yamanaka will receive its 26th annual Kyoto Prize in Advanced Technology, which for 2010 focuses on the fields of Biotechnology and Medical Technology. Dr. Yamanaka, 47, will receive the award for his pioneering work in developing a technology to generate pluripotent stem cells that does not require the use of human embryos.

18 Jun 2010

InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

InteKrin Therapeutics Inc. announced today it will present 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® pioglitazone, at the American Diabetes Association annual meeting in Orlando, FL, Monday, June 28, 2010 at 2:45 pm EDT during the "Update on BARI 2D --Treatment of Insulin Resistance" session.

18 Jun 2010

Physical fitness reduces metabolic risk in college students

Staying in shape may bolster the metabolic profiles of college students, even in those with higher than desirable body fat percentages. In an epidemiological study, researchers at the Friedman School of Nutrition Science and Policy at Tufts University found an association between physical fitness, body fat percentage and certain metabolic risk factors that are precursors to cardiovascular disease and Type 2 diabetes.

18 Jun 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.

18 Jun 2010

Roche implements risk mitigation plan in taspoglutide Phase III programme

Ipsen, a global biopharmaceutical group, today announced that its partner Roche today announced the implementation of a risk mitigation plan in the taspoglutide Phase III programme. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.

18 Jun 2010

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

Metabolon, Inc., the leader in metabolomics-based biomarker discovery and analysis, today announced the publication of research that identified a novel, early biomarker for insulin resistance and glucose intolerance in a nondiabetic population.

17 Jun 2010

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

17 Jun 2010

Biological mechanism associated with remission during pregnancy

During pregnancy, many women experience remission of autoimmune diseases like multiple sclerosis and uveitis. Now, scientists have described a biological mechanism responsible for changes in the immune system that helps to explain the remission.

17 Jun 2010

Teva exercises option to invest additional $11.9M in Andromeda Biotech

Andromeda Biotech Ltd. announces that Teva Pharmaceutical Industries Ltd. decided to exercise its option to invest in Andromeda Biotech Ltd. at a company per-money valuation of 170 million US dollars.

17 Jun 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).

17 Jun 2010

Researchers identify peptide that triggers diabetes

Researchers at National Jewish Health and the University of Colorado Anschutz Medical Campus have identified the precise protein fragment, or peptide, that can trigger diabetes in mice. The finding, published in the June 15, 2010, issue of the Proceedings of the National Academy of Sciences, supports an emerging theory about the origins of autoimmunity, and may lead to new diagnostic and therapeutic strategies in humans.

17 Jun 2010

Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome

Adi Mehta, MD stresses the growing severity of the metabolic syndrome in the May 2010 edition of Postgraduate Medicine. Metabolic syndrome often leads to cardiovascular disease (CVD) because of its key components: diabetes, dyslipidemia, and hypertension. With obesity maintaining its status as a huge problem worldwide, physicians must act as soon as possible when they recognize metabolic syndrome or any of its components.

16 Jun 2010

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

"Lap Band" weight loss surgery improves physical, psychological health in extremely obese adults

Spark Together for Health Kids program promotes access to physical activity, healthy food

Obese women with insulin resistance lose more weight on lower-carbohydrate diet: Study

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Research findings open door to new model for health and fitness measurement

Artificial pancreas system reduces risk of nocturnal hypoglycemia

Gladstone Institute researcher to receive Kyoto Prize in Advanced Technology

InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

Physical fitness reduces metabolic risk in college students

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Roche implements risk mitigation plan in taspoglutide Phase III programme

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

Biological mechanism associated with remission during pregnancy

Teva exercises option to invest additional $11.9M in Andromeda Biotech

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

Researchers identify peptide that triggers diabetes

Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in